33326 Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: June 14, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13354 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Monospecific 

CD22 Chimeric Antigen Receptor 

(CAR) Therapies for the Treatment of 

B-Cell Malignancies 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Syncopation 

Life Sciences Inc., (‘‘Syncopation’’), 

located in Palo Alto, California. 

DATES: Only written comments and/or 

complete applications for a license 

which are received by the National 

Cancer Institute’s Technology Transfer 

Center on or before July 9, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Jim Knabb, Senior 

Technology Transfer Manager, at 

Telephone: (240)–276–7856; or at Email: 

jim.knabb@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–080–2012–0: Human Monoclonal 

Antibodies Specific for CD22 

1. U.S. Provisional Patent Application 

61/042,329, filed April 4, 2008 (E–080– 

2008–0–US–01); 

2. International Patent Application 

PCT/US2009/039,080, Filed April 1, 

2009 (E–080–2008/0–PCT–02); 

3. U.S. Patent Application: 12/ 

934,214, filed September 23, 2010 (E– 

080–2008–0–US–03); 

4. U.S. Patent Application 13/959,061, 

filed August 5, 2015 (E–080–2008–0– 

US–04); 

5. U.S. Patent Application 15/012,023, 

filed February 1, 2016 (E–080–2008–0– 

US–05); 

6. U.S. Patent Application 15/424,238, 

filed February 3, 2017 (E–080–2008–0– 

US–06). 

E–291–2012–0: M971 Chimeric Antigen 

Receptors 

1. U.S. Provisional Patent Application 

61/717,960, filed October 24, 2012 (E– 

291–2012–0–US–01); 

2. International Patent Application 

PCT/US2013/060332, filed September 

18, 2013 (E–291–2012–0–PCT–02); 

3. Australia Application No: 

2019235926, filed September 2, 2020 

(E–291–2012–0–AU–03); 

4. Brazil Patent Application 

BR112015009003–6, filed April 22, 2015 

(E–291–2012–0–BR–04); 

5. Canada Application No: 2889055, 

filed September 18, 2013 (E–291–2012– 

0–CA–05); 

6. China Application No: 

201380061387.5, filed May 25, 2015 (E– 

291–2012–0–CN–06); 

7. European Patent Application No: 

13773468.7, filed September 18, 2013 

(E–291–2012–0–EP–07); 

8. India Patent Application No: 2344/ 

CHENP/2015, filed September 18, 2013 

(E–291–2012–0–IN–08); 

9. Japan Application No: 539602/ 

2015, filed April 24, 2015 (E–291–2012– 

0–JP–09); 

10. Russia Patent Application: 

2015117237, filed May 7, 2015 (E–291– 

2012–0–RU–10); 

11. U.S. Patent Application: 14/ 

437,889, filed April 23, 2015 (E–291– 

2012–0–US–11); 

12. Hong Kong Patent Application: 

16101891.0, filed February 19, 2016 (E– 

291–2012–0–HK–12); 

13. Russia Patent Application: 

2018116582, filed May 4, 2018 (E–291– 

2012–0–RU–13); 

14. Japan Patent Application: 2018– 

088908, filed May 2, 2018, (E–291– 

2012–0–JP–14); 

15. Australia Patent Application: 

2018204257, filed June 14, 2018 (E– 

291–2012–0–AU–16); 

16. U.S. Patent Application: 16/ 

107,271, filed August 21, 2018 (E–291– 

2012–0–US–17); 

17. Germany Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–DE–18); 

18. Spain Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–ES–19); 

19. France Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–FR–20); 

20. Great Britain Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–GB–21); 

21. Italy Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–IT–22); 

22. China Patent Application: 

201910500128.7, filed June 11, 2019 (E– 

291–2012–0–CN–23); 

23. U.S. Patent Application: 16/ 

869,792, filed May 8, 2020 (E–291– 

2012–0–US–24). 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

fields of use may be limited to the 

following: 

‘‘Development, manufacture and 

commercialization of chimeric antigen 

receptor T cell (CAR–T) 

immunotherapies (both autologous and 

allogeneically derived) for the treatment 

of B cell malignancies that express CD22 

wherein: 

1. The T cells are engineered to be 

monospecific for CD22; and 

2. The chimeric antigen receptor is 

specific for CD22 via the m971 scFv’’. 

This technology discloses CAR 

therapies that target CD22 by utilizing 

the anti-CD22 binder known as m971. 

CD22 is expressed on the surface of B 

cells in B cell malignancies and CD22- 

targeting CAR–T has shown early 

promise in clinical trials for ALL and 

NHL. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 33327 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 9, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–13260 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

The Role of Social Connectedness and 

Isolation on Health Outcomes. 

Date: July 12, 2021. 

Time: 1:00 p.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Biao Tian, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3089B, MSC 7848, Bethesda, 

MD 20892, (301) 402–4411, tianbi@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Medical Imaging. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Krystyna H. Szymczyk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–4198, szymczykk@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Psychopathology, Substance Abuse 

and Community-Based Interventions Across 

the Lifespan. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: David Erik Pollio, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1006F, 

Bethesda, MD 20892, polliode@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Radiation Therapy and Biology 

SBIR/STTR. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bo Hong, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6194, MSC 7804, Bethesda, MD 

20892, 301–996–6208, hongb@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

HIV Comorbidities and Clinical Studies 

Study Section. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: David C. Chang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 451–0290, changdac@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Antimicrobial Vaccine Development. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Barna Dey, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3184, 

Bethesda, MD 20892, 301–451–2796, bdey@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology and Bioengineering. 

Date: July 13–14, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Alexander Gubin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435– 

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Nutrition for Precision Health, powered by 

the All of Us Research Program: 

Metabolomics and Clinical Assays Center 

and Dietary Assessment Center. 

Date: July 13, 2021. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Latha Meenalochana 

Malaiyandi, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 812Q, Bethesda, MD 20892, (301) 435– 

1999, malaiyandilm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Animal and Biological Resource Centers and 

Resource-Related Research. 

Date: July 13, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Guoqin Yu, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–1276, guoqin.yu@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR18–877: 

Alzheimer’s Disease Clinical Trials. 

Date: July 13, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Louise Hargrave, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

Bethesda, MD 20892, (301) 443–7193, 

hargravesl@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–OD– 

19–022: Secondary Analyses of Existing 

Datasets of Tobacco Use and Health. 

Date: July 13, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Steven Michael Frenk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3141, 

Bethesda, MD 20892, frenksm@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Biology of Vision. 

Date: July 13, 2021. 


khammond on DSKJM1Z7X2PROD with NOTICES